CBT-004 is under clinical development by Cloudbreak Therapeutics and currently in Phase II for Unspecified Ophthalmological Disorders. According to GlobalData, Phase II drugs for Unspecified Ophthalmological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CBT-004 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CBT-004 overview
CBT-004 is under development for the treatment of the vascularized pinguecula disease. It is administered through ophthalmic route in the form of emulsion. The drug candidate is a potent multi-kinase inhibitor of platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR).
Cloudbreak Therapeutics overview
Cloudbreak Therapeutics, a clinical-stage biotechnology company that focusing on ocular drug development. The company is headquartered in United States.
For a complete picture of CBT-004’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
